How Endometrial Cancer Treatment Is Planned: Surgery First, Then What the Pathology Says

The sentence that unsettles people most in the gynecologic oncology clinic is not the diagnosis itself. It is the one that comes a few minutes later: “We’ll know more after the operation.” For someone who has just been told they have endometrial cancer, that sounds like hedging. It isn’t. It is an honest description of how this cancer is managed, and understanding why makes the whole plan feel less like a fog.

Endometrial cancer treatment by stage is real, but the stage is only fully known once a pathologist has examined the removed uterus under a microscope. The biopsy that made the diagnosis saw a fragment. The operation delivers the whole picture: how deep the tumor grew, whether it touched the cervix, whether lymph nodes are involved, what the cells look like, and increasingly, which molecular features they carry.

This article walks through that sequence in the order a care team actually thinks about it, with the caveats the evidence demands.

Why surgery usually comes first, and what actually happens during it

Most cancers are staged with scans before anyone operates. Endometrial cancer is different. Its standard staging is surgical, meaning the stage is assigned from what the surgeon finds and what the pathologist confirms, not from imaging alone. That is why the operation tends to be the first step rather than the last: it removes the tumor and, in the same sitting, answers the questions that shape everything afterward. The National Cancer Institute’s PDQ summary describes surgery as the primary treatment for most endometrial cancers precisely for this dual role.

The core procedure is a total hysterectomy, removal of the uterus and cervix, almost always combined with bilateral salpingo-oophorectomy, removal of both fallopian tubes and ovaries. The ovaries are taken because endometrial tumors can spread to them and because many are fueled by estrogen the ovaries produce. Surgeons also assess lymph nodes, the small filters of the immune system along the pelvic blood vessels. Some teams remove a sample of nodes; many now use sentinel lymph node mapping, in which a dye injected into the cervix travels to the first nodes draining the uterus so only those are removed and examined. A wash of fluid across the abdomen may be collected to look for stray cells.

Much of this is done through small incisions with a laparoscope or robotic instruments. The Mayo Clinic notes minimally invasive approaches are common and generally mean a shorter hospital stay, though an open incision is still chosen when a uterus is very large or disease has clearly spread. The uterus is removed intact, never broken up, so the pathologist can read its architecture and so no cells are scattered.

The operation, in other words, is both the treatment and the test. Its results arrive as a pathology report a week or two later, and that report, not the surgeon’s impression on the day, sets the stage.

Endometrial cancer staging explained: what stages 1 to 4 describe

Staging answers one question: how far has the cancer traveled from the lining where it began? The endometrium is the inner lining of the uterus; beneath it lies the myometrium, the thick muscular wall. Tumors begin in the lining and, over time, may grow into that wall, reach the cervix, exit the uterus into the pelvis, involve lymph nodes, or seed distant organs. The stage is a map of that journey, and the National Cancer Institute’s PDQ summary lays out the standard four-stage system.

Stage 1 means the cancer is confined to the body of the uterus. It is split by depth: stage 1A tumors sit in the lining or invade less than half of the muscle wall, while stage 1B tumors reach half or more. Stage 2 means the tumor has grown into the supporting tissue of the cervix but no further. Stage 3 describes spread beyond the uterus but still within the pelvic region: to the outer surface of the uterus, the ovaries or tubes, the vagina, or pelvic and para-aortic lymph nodes, the latter being nodes along the main artery in the abdomen. Stage 4 means the cancer has invaded the bladder or bowel lining, or has spread to distant sites such as the lungs, liver, bones or lymph nodes far from the pelvis.

Two points deserve emphasis. First, according to NCI, most endometrial cancers are found while still confined to the uterus, largely because the cancer tends to announce itself early with abnormal bleeding. Second, the staging system has been revised in recent years to fold in tumor grade, cell type and molecular features, so two clinicians may quote slightly different substage labels for the same tumor. The letters matter less than the underlying facts: depth, spread, grade and biology. Ask your team to translate the label into those four plain descriptions.

What the pathology report says, and why it drives everything after surgery

A pathology report can run several pages and reads like another language. Four elements carry most of the weight in planning further treatment.

Histologic type is the family the cancer cells belong to. Endometrioid tumors, which resemble normal lining cells, are the most common and often behave less aggressively. Serous, clear cell, undifferentiated and carcinosarcoma types, sometimes grouped as non-endometrioid or high-risk histologies, tend to behave more aggressively regardless of how confined they appear. NCI’s PDQ summary treats these as a distinct planning category.

Grade describes how abnormal the cells look on a scale of 1 to 3. Grade 1 cells still form recognizable glands; grade 3 cells have largely lost that organization. Higher grade generally signals faster growth.

Depth and extent covers how far into the muscle wall the tumor grew, whether it reached the cervix, whether lymph nodes contained cancer, and whether tumor cells were seen inside small blood or lymph vessels, a finding called lymphovascular space invasion. That last finding is a marker of increased risk of recurrence even when nodes are clear.

Molecular profile is the newest layer. Pathologists now commonly test for mismatch repair deficiency, a fault in the cell’s DNA-proofreading system; for abnormal p53, a damaged tumor-suppressor protein; and sometimes for POLE mutations, a change that paradoxically marks tumors with a favorable outlook. Tumors with none of these are labeled “no specific molecular profile.” These groupings help predict behavior and, in the case of mismatch repair deficiency, point toward immunotherapy and toward testing for Lynch syndrome, an inherited cancer risk condition.

Together, these findings sort a tumor into a risk group: low, intermediate, high-intermediate or high. The group, more than the stage number alone, determines what is offered next.

Endometrial cancer treatment by stage: how the plan typically changes from stage 1 to stage 4

With the report in hand, the tumor board, a meeting of surgeons, medical oncologists, radiation oncologists and pathologists, assembles a plan. The table below summarizes what guideline summaries from NCI and the NHS describe as typical approaches. It is a map of common patterns, not a prescription; risk group, cell type, molecular findings, general health and personal priorities all shift the recommendation.

Stage and risk group	Usual first step	What commonly follows surgery
Stage 1A, low grade, endometrioid, no adverse features	Hysterectomy with tubes and ovaries removed; node assessment	Observation with scheduled follow-up; no further treatment in many cases
Stage 1 with adverse features (deeper invasion, higher grade, vessel invasion)	Same surgery	Vaginal brachytherapy is often considered; external beam radiation or chemotherapy for higher-risk combinations
Stage 2	Hysterectomy, sometimes more extensive around the cervix	Radiation to the pelvis and/or vagina; chemotherapy considered for high-risk histology
Stage 3	Surgery to remove all visible disease when feasible	Chemotherapy, often combined with radiation; immunotherapy alongside chemotherapy for eligible tumors
Stage 4 or recurrent disease	Surgery only when it can meaningfully reduce disease or relieve symptoms; often systemic therapy first	Chemotherapy with or without immunotherapy; hormone therapy for low-grade, receptor-positive tumors; radiation for symptom control
Any stage, non-endometrioid histology (serous, clear cell, carcinosarcoma)	Comprehensive surgical staging	Chemotherapy commonly recommended even for early stage, often with radiation

Read across a row and a pattern emerges: the deeper and more aggressive the tumor, the more treatment shifts from local, aimed at the pelvis, to systemic, aimed at the whole body. That is the logic of the entire plan. Local therapies such as surgery and radiation work where the disease is known to be; systemic therapies such as chemotherapy, immunotherapy and hormone therapy travel to wherever it might be hiding.

Who usually has surgery first, and who is usually asked to wait or take a different route

For the majority of people, the sequence is straightforward: diagnosis by biopsy, imaging to look for obvious spread, then surgery within weeks. NCI’s PDQ summary describes hysterectomy as the standard initial treatment for cancer that appears confined to the uterus. But several groups are routinely steered differently, and it helps to know which.

People whose scans suggest widespread disease. When imaging shows cancer in distant organs, an operation to remove the uterus may not change the course of the illness and carries its own recovery burden. Teams often begin with systemic treatment and revisit surgery later if the disease responds or if the uterus is causing bleeding or pain.

People for whom anesthesia and major surgery carry high risk. Endometrial cancer is most often diagnosed after menopause, according to the Mayo Clinic, and some patients live with heart, lung or kidney conditions that make a long operation dangerous. For them, radiation to the uterus, hormone therapy, or a smaller operation may be proposed instead. This is a judgment about safety, not a judgment about the person.

People who want to preserve fertility. A narrow group, typically younger, with grade 1 endometrioid tumors that appear confined to the lining with no muscle invasion on high-quality imaging, may be offered progestin therapy, a synthetic form of progesterone, with repeat biopsies every few months instead of immediate hysterectomy. NCI notes this is investigational and demands close surveillance; hysterectomy is generally still advised once childbearing is complete or if the tumor fails to respond.

People with a suspected inherited syndrome or an uncertain diagnosis. A repeat biopsy, a hysteroscopy (a camera examination inside the uterus), or genetic counseling may come before surgery so the operation can be planned properly.

Being asked to wait is not the same as being denied treatment. It usually means the team is sequencing the steps so that the first one does the most good.

What the first weeks after a hysterectomy usually look like

The operation ends; the waiting begins. Two timelines run in parallel over the following weeks, one for the body and one for the pathology report, and both deserve honest expectations.

For the body, the pattern depends on how the surgery was done. After minimally invasive surgery, many people go home within a day or two; after an open incision, the hospital stay is typically longer. The NHS advises that full recovery from an abdominal hysterectomy takes about six to eight weeks, with keyhole approaches often shorter, though it stresses that everyone recovers at their own pace. Expect fatigue that outlasts the wound pain, some vaginal spotting or discharge for a few weeks, and bowel sluggishness in the first days. Walking early and often is encouraged both for recovery and to reduce the risk of blood clots in the legs, a recognized complication after pelvic surgery. Lifting, driving and sexual activity are usually deferred until the team clears them; the NHS gives typical ranges for each.

If the ovaries were removed before natural menopause, hot flashes, sleep disturbance and mood changes can begin within days. This surgical menopause is abrupt rather than gradual, and it is worth naming in advance so it is not mistaken for something more alarming.

For the report, most centers have the final pathology within one to two weeks. A follow-up appointment is then scheduled to walk through the findings and any recommendation for further treatment. If radiation or chemotherapy is advised, it typically starts once the incisions have healed, often several weeks after surgery, so the two timelines converge rather than collide.

The emotional weather during this window is often the hardest part. People describe feeling suspended, physically recovering from something while not yet knowing whether it was enough. Knowing that the gap is built into the process, not a sign that something is wrong, can soften it.

Endometrial cancer treatment after hysterectomy: observation, brachytherapy, external beam and chemotherapy

Treatment given after surgery to reduce the chance of the cancer returning is called adjuvant therapy. Not everyone needs it. Deciding who does is the central job of the pathology review, and the options fall along a spectrum from doing nothing more to doing a great deal.

Observation is the recommendation for many low-risk stage 1 tumors. NCI’s PDQ summary notes that for cancer confined to the uterus with favorable features, surgery alone is standard, followed by scheduled check-ups. Choosing observation is an active decision grounded in evidence that additional treatment would add side effects without measurable benefit for that group.

Vaginal brachytherapy places a radiation source directly inside the upper vagina for a few minutes at a time over a handful of outpatient sessions. Its purpose is to treat the vaginal cuff, the most common site of recurrence after hysterectomy, while sparing the bladder and bowel. It is frequently considered for intermediate-risk tumors.

External beam radiation aims a machine at the whole pelvis, covering the lymph node regions as well. The NHS describes it as delivered in short daily sessions on weekdays across several weeks. It is used when the risk of recurrence in the pelvis or nodes is judged higher, and it carries more bowel and bladder side effects than brachytherapy.

Chemotherapy uses medicines, most commonly a platinum agent paired with a taxane, that circulate through the bloodstream to damage rapidly dividing cells anywhere in the body. It is recommended for stage 3 and 4 disease and for early-stage tumors with aggressive cell types. It is given in cycles, usually every few weeks over several months, with the schedule set by the oncologist. Combining chemotherapy with radiation is common for stage 3.

The choice among these is not a ladder where more is always better. It is a matching exercise between the tumor’s risk profile and the treatment most likely to address it.

Where immunotherapy and hormone therapy fit into the plan

Two categories of systemic treatment work very differently from chemotherapy and are increasingly part of the conversation, particularly for advanced or recurrent disease.

Immunotherapy, specifically immune checkpoint inhibitors, does not attack the cancer directly. It releases a brake that tumors use to hide from the immune system, so the body’s own T cells can recognize and destroy them. Endometrial cancers with mismatch repair deficiency accumulate an unusual number of mutations, which makes them look more foreign to the immune system and more responsive to this approach. NCI’s PDQ summary notes checkpoint inhibitors as an option for advanced or recurrent endometrial cancer, and they are now commonly combined with chemotherapy for stage 3 and 4 disease in eligible patients. Side effects come from the immune system becoming overactive and can affect the thyroid, bowel, skin, liver or lungs, which is why symptoms during treatment are reported promptly. Whether immunotherapy is appropriate, and for how long, sits with the medical oncologist.

Hormone therapy exploits the fact that many endometrial cancers, particularly low-grade endometrioid tumors, carry receptors for estrogen and progesterone and grow in response to estrogen. Progestins, aromatase inhibitors, which block estrogen production, and related agents slow that growth. NCI describes hormone therapy as an option for advanced, recurrent or receptor-positive disease, and for the small fertility-preserving group discussed earlier. It tends to be gentler than chemotherapy but slower and less powerful, so it is generally reserved for tumors with the right biology and for people whose disease is not rapidly progressing.

Neither treatment is a general-purpose replacement for surgery or chemotherapy. They are precise tools, and their use depends on test results, mismatch repair status and hormone receptor status, that come from the pathology report. This is one more reason the report, not the diagnosis alone, dictates the plan.

How fast does endometrial cancer spread? What the evidence actually shows

This question hides an anxiety: if I wait three weeks for surgery, will the cancer race ahead? The honest answer has several parts.

There is no single speed. The most common type, low-grade endometrioid cancer, is typically slow-growing; it often develops from a precursor state called atypical hyperplasia, an overgrowth of lining cells with abnormal features, over a period that can span years. High-grade endometrioid tumors and non-endometrioid types such as serous cancer behave more aggressively and can spread earlier relative to their size. The pathology report’s grade and histology are therefore the best available indicators of tempo, which is another reason clinicians hold off on detailed predictions until they have it.

The pattern of spread is well described. According to NCI’s PDQ summary, endometrial cancer typically grows first into the muscle wall, then toward the cervix or out through the uterine surface, reaches pelvic and para-aortic lymph nodes, and only later travels via the bloodstream to distant organs. This stepwise pattern is why depth of invasion and node status are such strong predictors, and why most tumors are still confined to the uterus at diagnosis.

Bleeding tends to appear early. The Mayo Clinic identifies abnormal vaginal bleeding, especially after menopause, as the most common symptom, and because it occurs while the tumor is still small, it acts as an early warning that many other cancers lack. This is the single most important fact for anyone with postmenopausal bleeding: the symptom is worth acting on promptly, and acting on it usually means the cancer, if present, is found early.

On timing of surgery, guideline bodies consider a period of weeks between diagnosis and operation reasonable for most early-stage tumors. Your surgeon will schedule according to your tumor’s features and your medical fitness, not by a universal clock.

Stage 4 endometrial cancer: symptoms, goals of treatment, and how life expectancy questions are answered honestly

Stage 4 means the cancer has reached the bladder or bowel lining or has spread to distant sites. The goals of treatment shift. The aim becomes controlling the disease for as long as possible, easing symptoms and protecting quality of life, and treatment plans are revisited as the cancer responds or changes.

Symptoms at this stage reflect where the disease is. Persistent vaginal bleeding may continue. Pelvic or abdominal pain, bloating or swelling from fluid, changes in bowel or bladder habits, loss of appetite and unintended weight loss, fatigue, and shortness of breath if the lungs are involved are all described in the Cleveland Clinic’s and NCI’s overviews of advanced uterine cancer. None of these symptoms is specific to cancer, and none should be used to self-stage; their value is in prompting a conversation with the team about what is causing them and what can relieve them.

Treatment usually leads with systemic therapy: chemotherapy, often combined with immunotherapy for eligible tumors, or hormone therapy for slower low-grade, receptor-positive disease. Surgery may be used to remove bulky disease or relieve bleeding; radiation can shrink a painful deposit or stop bleeding. Palliative care, specialist support focused on symptom relief, can run alongside active treatment from the outset and is not a signal that treatment is ending.

On life expectancy, the honest response is that population statistics describe groups, not individuals. Published survival figures pool people of different ages, cell types, molecular profiles and responses to treatment, and many were gathered before immunotherapy entered routine use. NCI publishes stage-based statistics for those who want them, and your oncologist can explain how your own tumor’s features and your response to the first treatments place you within that range. Asking “what do you expect for someone in my situation, and how will we know if the treatment is working?” tends to yield a more useful answer than a single number.

Fertility, menopause and Lynch syndrome: the conversations that happen alongside planning

Three topics tend to arrive uninvited during endometrial cancer treatment planning. Each deserves its own appointment, and each is easier when raised early.

Fertility. Hysterectomy ends the possibility of carrying a pregnancy. For younger patients with early, low-grade tumors, the progestin-based approach described earlier can, in selected cases, defer surgery; NCI stresses that this requires strict criteria and repeat biopsies, and that it is not standard care. For anyone considering it, a reproductive endocrinologist should be part of the team before decisions are finalized. Egg or embryo preservation before treatment is a separate option that a fertility specialist can discuss.

Menopause. Removing the ovaries before natural menopause triggers an immediate hormonal drop. Symptoms can be intense, and long-term bone and heart health become relevant. Whether menopausal hormone therapy is safe after endometrial cancer depends on the tumor’s stage, grade and receptor status; NCI notes this as an area of ongoing evaluation, and the decision belongs to the oncology team in discussion with the patient. Non-hormonal strategies for hot flashes and sleep exist and can be started without waiting for that decision.

Lynch syndrome. This inherited condition, caused by faults in mismatch repair genes, raises lifetime risk of endometrial and colorectal cancers. MedlinePlus and NCI both note that tumors showing mismatch repair deficiency should prompt consideration of genetic counseling and, where indicated, germline testing, meaning a blood test for inherited gene changes. A positive result matters beyond the patient: it changes screening advice for siblings and children, and it alters the patient’s own colorectal surveillance schedule. Since mismatch repair testing is now routine on the tumor itself, ask whether yours was tested and what the result means for your family.

None of these conversations changes the core surgical plan, but each shapes the life around it.

What people often get wrong about endometrial cancer treatment by stage

Cancer forums and family lore generate a reliable set of misunderstandings. Correcting them removes unnecessary fear and, occasionally, unnecessary treatment requests.

“Stage 1 means no further treatment.” Often, but not always. A stage 1 tumor with deep invasion, high grade or aggressive cell type can carry more risk than its label suggests, and adjuvant radiation or chemotherapy may be recommended. Stage is a map of location; risk group adds grade and biology, and the plan follows the risk group.

“If the scan looked clear, surgery was just a formality.” Imaging cannot reliably measure how deeply a tumor has grown into the muscle wall or detect microscopic node involvement. Surgical staging is the standard for this cancer precisely because scans underestimate or overestimate spread in a meaningful share of cases.

“More treatment is always safer.” Clinical trials cited in NCI’s PDQ summary show that for low-risk early-stage disease, adding pelvic radiation or chemotherapy increases side effects without improving outcomes. Observation is an evidence-based recommendation, not an omission.

“Chemotherapy is only for stage 4.” Serous, clear cell and carcinosarcoma tumors are commonly treated with chemotherapy even when confined to the uterus, because their cell type predicts a higher tendency to spread.

“Hormone therapy is a gentle alternative for anyone.” It works for tumors with hormone receptors, mostly low grade, and is generally too slow for aggressive or rapidly progressing disease.

“Recurrence means treatment failed.” Recurrence reflects cancer biology, not a mistake by the patient or the team. Many recurrences, particularly isolated ones in the vagina or pelvis, can be treated again with radiation, surgery or systemic therapy.

“The pathology delay means something is wrong.” Careful microscopic and molecular analysis takes one to two weeks for most laboratories. Waiting is the process working, not stalling.

Questions to ask your care team

The most useful questions are the ones that convert a stage label into concrete facts about your tumor and your plan. Bringing a written list, and someone to take notes, helps in appointments where information arrives fast.

• What type of endometrial cancer do I have, and what grade? Is it endometrioid or one of the higher-risk cell types?
• How deep did the tumor grow into the uterine wall, and did it reach the cervix?
• Were lymph nodes examined? How many, by what method, and were any involved?
• Was lymphovascular space invasion seen?
• Which molecular tests were run on my tumor: mismatch repair, p53, POLE, hormone receptors? What did they show, and how do they change the plan?
• Which risk group does my tumor fall into, and what does the evidence say about further treatment for that group?
• If you are recommending observation, what will follow-up involve and how often?
• If you are recommending radiation, which type, over roughly how many weeks, and what side effects should I prepare for?
• If chemotherapy or immunotherapy is proposed, what is the goal: reducing recurrence risk or controlling known disease? How will we measure whether it is working?
• Should I be referred for genetic counseling, and does my result affect my family?
• How will surgical menopause be managed, and which symptom treatments are considered safe for my tumor type?
• Are there clinical trials appropriate for my situation?
• Who do I call, and at what number, if I develop symptoms between appointments?
• If I want a second opinion on the pathology or the plan, how do I arrange that?

A team that welcomes these questions is showing you how the plan was built. If an answer is “we don’t know yet,” ask what result or event will provide the answer and when it is expected. The unknowns in endometrial cancer planning are usually scheduled, not open-ended.

When to call your doctor

Before diagnosis, during treatment and for years afterward, certain signs warrant a same-day call to your care team or, in some cases, emergency care. They are not a checklist for self-diagnosis; they are the situations in which waiting for the next scheduled appointment is the wrong choice.

Before or after treatment: any vaginal bleeding after menopause, even a single episode of spotting, or bleeding between periods or heavier than usual before menopause. The Mayo Clinic and NHS both identify this as the symptom most often leading to diagnosis and the one most worth acting on quickly. New pelvic pain, persistent bloating, or unexplained weight loss also merit prompt review, particularly in the years after treatment when recurrence is being watched for.

After surgery: fever, wound redness or discharge, heavy bleeding, worsening rather than improving abdominal pain, inability to pass urine, or persistent vomiting. Seek emergency care for calf pain with swelling, sudden chest pain, or breathlessness, which can signal a blood clot, a recognized risk after pelvic surgery.

During radiation or chemotherapy: a temperature at or above the threshold your team specifies, shaking chills, uncontrolled diarrhea, severe mouth sores, or any symptom your team has flagged for your regimen. Chemotherapy can lower white blood cell counts, so fever needs urgent assessment.

During immunotherapy: new severe diarrhea, shortness of breath, rash, yellowing of the skin or eyes, severe headache or confusion, or profound fatigue, which can indicate an immune reaction against a healthy organ.

Your team will give you a direct number for out-of-hours concerns. Use it. Oncology teams would far rather field a call about a symptom that turns out to be minor than learn about a serious one late.

Frequently asked questions

How fast does endometrial cancer spread?

It depends on the tumor’s type and grade, which is why clinicians wait for pathology before predicting tempo. Low-grade endometrioid tumors, the most common kind, usually grow slowly and often develop from a precancerous overgrowth over years. High-grade and serous tumors can spread more quickly relative to their size. Spread typically follows a stepwise path: into the uterine wall, then to lymph nodes, and only later to distant organs.

What are the treatment options for endometrial cancer after a hysterectomy?

Options range from observation with scheduled follow-up to vaginal brachytherapy, external beam pelvic radiation, chemotherapy, immunotherapy or hormone therapy, alone or in combination. Which is offered depends on the pathology report: cell type, grade, depth of invasion, lymph node involvement and molecular features. Low-risk tumors often need nothing further; higher-risk tumors are more likely to receive radiation, chemotherapy or both. The treating team decides with you.

What is the life expectancy for stage 4 endometrial cancer with treatment?

No single figure applies to an individual. Population statistics pool people with different cell types, molecular profiles, ages and responses to treatment, and many predate the routine use of immunotherapy. The National Cancer Institute publishes stage-based statistics for those who want them. Your oncologist can explain how your tumor’s features and early response to treatment shape expectations, and how the team will judge whether treatment is working.

What are the common symptoms of stage 4 endometrial cancer?

Symptoms reflect where the cancer has spread and can include persistent vaginal bleeding, pelvic or abdominal pain, bloating or swelling from fluid, changes in bowel or bladder habits, appetite loss, unintended weight loss, fatigue and breathlessness if the lungs are involved. None is specific to cancer, and they cannot be used to determine stage at home. Their value is in prompting a conversation with the care team about cause and relief.

Can endometrial cancer staging be explained without surgery?

Only provisionally. Scans and biopsy give a clinical estimate, but standard staging for this cancer is surgical because imaging cannot reliably measure depth of invasion into the muscle wall or detect microscopic lymph node involvement. The final stage is assigned from the pathologist’s examination of the removed uterus and nodes. When surgery is not possible, teams stage clinically and plan accordingly.

Does everyone with endometrial cancer need chemotherapy?

No. Chemotherapy is generally recommended for stage 3 and 4 disease and for early-stage tumors with aggressive cell types such as serous, clear cell or carcinosarcoma. Many people with low- or intermediate-risk stage 1 disease need no chemotherapy at all; they are followed with observation or offered radiation to the vagina. The pathology report, not the diagnosis alone, determines whether chemotherapy is proposed.

What is the difference between brachytherapy and external beam radiation for endometrial cancer?

Brachytherapy places a radiation source directly inside the upper vagina for a few minutes per session over a small number of outpatient visits, targeting the most common site of recurrence while sparing bowel and bladder. External beam radiation treats the whole pelvis, including lymph node areas, in daily weekday sessions over several weeks, with more bowel and bladder side effects. Risk group guides which, if either, is offered.

Why does the pathology report take so long after surgery?

Careful processing takes time. The uterus must be fixed, sliced and examined under the microscope to measure depth of invasion, assess the cervix, review every lymph node and identify vessel invasion. Molecular tests for mismatch repair, p53 and hormone receptors add further steps. Most laboratories report within one to two weeks. The wait is the process working properly rather than a sign of concern.

Can I keep my ovaries during surgery for endometrial cancer?

Usually the ovaries and fallopian tubes are removed with the uterus, because the cancer can spread to them and because many tumors grow in response to ovarian estrogen. In selected younger patients with low-grade, early tumors, some teams discuss preserving the ovaries to avoid abrupt menopause, weighing that against risk. This is an individualized decision made with the gynecologic oncologist before the operation.

What does mismatch repair deficiency mean on my endometrial cancer report?

It means the tumor cells have lost a DNA-proofreading system, causing them to accumulate many mutations. Such tumors tend to respond well to immune checkpoint inhibitors, a form of immunotherapy, which may be considered for advanced or recurrent disease. The finding also raises the possibility of Lynch syndrome, an inherited condition, so genetic counseling and germline testing are typically recommended, with implications for relatives.

References

• Uterine Cancer, Cleveland Clinic
• Womb (uterus) cancer – Treatment, NHS
• Hysterectomy – Recovery, NHS
• Uterine Cancer, MedlinePlus

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.